Carterra Moves Forward to Commercialize LSA Platform

Label-free biosensor company Carterra plans to use the proceeds from the recent closing of a $10M financing from Telegraph Hill Partners to complete development and commercialize the company’s  LSA™ instrument, a fully automated, high-throughput monoclonal antibody (mAb) characterization platform based on surface plasmon resonance.The LSA enables label-free binding experiments to be carried out and to allow high-resolution data to be obtained early in the drug discovery process